Cardiol is leveraging its expertise in drug encapsulation technologies and pharmaceutical cannabinoids to develop proprietary formulations of drugs for commercial development in three important medical markets:
- Commercializing a line of pharmaceutically-manufactured pure cannabidiol products in 2019 in the growing market for medical cannabinoids.
- Developing nanoformulations designed to target anti-inflammatory drugs, including cannabidiol, to the heart for the treatment of heart failure.
- Pursuing an immunotherapeutics program commencing with an innovative cancer immunotherapeutic in combination with cannabinoids for Glioblastoma Multiforme, a Fast Track eligible Orphan Indication.
* Cardiol will advance the most promising nanoformulations for HF into clinical development.